Zelira Therapeutics Meets Primary Endpoints for Phase (1b/2a) Medicinal Cannabis Trial for Insomnia
•23 chronic insomnia patients treated with ZLT-101, Zelira’s proprietary and patented medicinalcannabis formulation, demonstrated statistically significant improvement in Insomnia SeverityIndex scores compared to placebo
•ZLT-101 therapy was well tolerated, with no serious adverse events reported
•Positive trial results an important milestone for Zelira
•Poised to launch world’s first clinically validated medicinal cannabis product for insomnia in 2020
•Expands Zelira’s product portfolio alongside the HOPETM product range
Here we go...
- Forums
- ASX - By Stock
- Ann: Trading Halt
Zelira Therapeutics Meets Primary Endpoints for Phase (1b/2a)...
Featured News
Add ZLD (ASX) to my watchlist
(20min delay)
|
|||||
Last
63.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.148M |
Open | High | Low | Value | Volume |
63.0¢ | 63.0¢ | 63.0¢ | $5.841K | 9.271K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1557 | 64.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
70.0¢ | 2332 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1557 | 0.640 |
2 | 2299 | 0.630 |
1 | 500 | 0.620 |
1 | 830 | 0.610 |
4 | 5415 | 0.600 |
Price($) | Vol. | No. |
---|---|---|
0.700 | 2332 | 1 |
0.730 | 157 | 1 |
0.750 | 2000 | 1 |
0.760 | 3933 | 1 |
0.930 | 6000 | 1 |
Last trade - 14.22pm 24/07/2024 (20 minute delay) ? |
Featured News
ZLD (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online